Thrombin is an allosteric enzyme existing in two forms, slow and fast, that differwidely in their specificities toward synthetic and natural amide substrates. The two forms are significantly populated in vivo, and the allosteric equilibrium can be affected by the binding of effectors and natural substrates. The fast form is procoagulant because it cleaves fibrinogen with higher specificity; the slow form is anticoagulant because it cleaves protein C with higher specificity. Binding of thrombomodulin inhibits cleavage of fibrinogen by the fast form and promotes cleavage of protein C by the slow form. The allosteric properties of thrombin, which has targeted two distinct conformational states toward its two fundamental and competing roles in hemostasis, are paradigmatic of a molecular strategy that is likely to be exploited by other proteases in the blood coagulation cascade.
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The physiologic response to a vascular lesion entails a number of sequential enzymatic steps catalyzed by distinct serine proteases (1, 2). The cascade of events culminates in the generation of thrombin, which then catalyzes the conversion of fibrinogen into fibrin monomers, leading to clot formation. Efficiency of the coagulation system requires that the response be rapid, localized at the injury site, and then readily terminated. This result is accomplished through a complex network of regulatory interactions. The components of this network share a surprisingly high degree of structural homology (3) . Hence, a crucial question arises as to the molecular origin of specificity in the cascade. Is there an underlying molecular strategy shared by different members of the cascade or is specificity accomplished differently by each protease? Understanding the physicochemical and structural basis of protease specificity in the coagulation cascade would provide new tools for engineering proteases of desired specificity and eventually lead to more efficient pharmacological strategies for controlling hemostasis.
Thrombin function conveys most of the complexity of the entire coagulation cascade. This enzyme accomplishes two opposite roles in hemostasis. The procoagulant role entails conversion of fibrinogen into the fibrin clot and enhancement of its own conversion from prothrombin through feed-back activation of proteases upstream in the cascade. The anticoagulant role encompasses activation of protein C (PC) with participation of thrombomodulin (TM), a cofactor on the membrane of endothelial cells (4) (5) (6) . Activated protein C (APC) rapidly inactivates factors Va and VIIIa, both of which are involved in thrombin generation. Thrombin, therefore, finely tunes its own production in the blood through the balance between positive and negative feed-back loops, and much interest now exists in understanding the molecular mechanism that allows this enzyme to accomplish its dual role in hemostasis (7, 8) .
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We recently demonstrated that thrombin is an allosteric enzyme, present in two distinct forms in equilibrium: the slow and fast forms (9, 10) . These forms were so defined originally from their ability to interact with and cleave small chromogenic amide substrates; the slow form shows a significantly reduced catalytic efficiency. Because the two forms are significantly populated under physiological conditions (9, 11) , assessing their role in the procoagulant and anticoagulant activities of the enzyme is important.
MATERIALS AND METHODS
Human a-thrombin was purified and tested for activity as described (9, 12) . Human fibrinogen, PC, APC, and rabbit lung TM of the highest purity and activity were from Hematologic Technologies (Essex Junction, VT). These reagents yielded results consistent with published data (see Results). The chromogenic substrate S2266 (H-D-Val-Leu-Arg-p-nitroanilide), specific for APC, was from Chromogenix (Molndal, Sweden).
The slow and fast forms were studied under experimental conditions of 5 mM Tris/0.1% PEG (pH 8.0) at 25°C. Ionic strength was kept constant at 200 mM with NaCl, when studying the fast form, or with choline (Ch) chloride, when studying the slow form (9, 10). In studies involving PC, the slow form of thrombin was studied under conditions of 195 mM ChCl/5 mM NaCl (see below).
Release of fibrinopeptides A and B (FpA and FpB) by the slow and fast forms was quantified by reverse-phase HPLC, using a Waters 717plus Autosampler for 1-ml injections into the HPLC system equipped with a Waters C18 column (4.6 x 250 mm). Elution was done at a flow rate of 1 ml/min, with a gradient containing 80 mM sodium phosphate buffer, pH 3.1 (solvent A) and acetonitrile (solvent B). Optimal separation was obtained by using 17% of solvent B from 0 to 15 min, followed by a 10-min linear gradient to 40% of solvent B. The effluent was monitored at 205 nm. Extinction coefficients for FpA and FpB were derived by calibration and quantitative amino acid analysis of highly pure standards. The sequential release of FpA and FpB was analyzed according to the mechanism of Shafer and coworkers (13) [5] and TKm Tkt T + S <'TS T + P. [6] The product P is the p-nitroaniline released from a chromogenic substrate (S2266) specific for APC and provides the signal to be followed at 405 nm as a function of time. 10 nM had no effect on activity of APC, regardless of solution conditions, and 5 mM Ca2' had no effect under all conditions studied in 0.2 M NaCl. Progress curves of S2266 hydrolysis were measured to derive the specificity (kcat/Km ratio for Eq. 4) of the slow and fast forms toward PC. The S2266 concentration was 50 ,uM in all cases, and PC was used at 300 nM, well below estimated Km values (19) . The thrombin concentration was 2 nM. Under these conditions release of p-nitroaniline due to cleavage by thrombin and APC was extremely sensitive to the kcat/Km ratio for PC activation, thereby allowing accurate measurements of this parameter; this was due to the constraints imposed by the parallel Eqs. 5 and 6 that were studied independently. The robustness of the results was checked extensively by KINSIM with various combinations of kinetic rates for substrate binding, dissociation, acylation, and deacylation for thrombin and APC. All combinations consistent with the Tkcat/TKm and Ckcat/CKm ratios determined independently led to the same value of kcat/Km for PC activation by thrombin. Activation of PC was practically complete under all conditions studied. Product inhibition was carefully checked and ruled out by independent measurements of Tkcat, TKm. Ckcat, and CKm using initial velocity determinations. These measurements yielded specificity ratios in agreement with those determined by progress curves.
RESULTS
The functional properties of the slow and fast forms of thrombin are summarized in Tables 1 and 2 . Thrombomodulin binds to the fast form with an affinity about four times higher (see Fig. 1 enzyme but that are not responsible for binding of the hirudin tail. This conclusion agrees with recent structural data (20) .
The difference in AG, between fibrinogen, hirudin, and TM is from the contribution of the region around the catalytic pocket of the enzyme that is sensitive to the allosteric transition and interacts with the N-terminal domains of hirudin and the fibrinogen Aa chain but does not interact with TM.
Previous kinetic studies indicated that the fast form cleaves a number of synthetic amide substrates with higher efficiency (9) . Consistent with these findings, FpA and FpB are cleaved by the fast form with higher specificity (Fig. 2) , indicating that this form is responsible for the procoagulant activity. Both forms obey Shafer's sequential mechanism for release of fibrinopeptides, with FpB being released after FpA. The value of AGc in Table 2 is related to the specificity ratio and reflects linkage between the stabilization of the transition state and the slow--fast transition. The differences between FpA and FpB contain important clues as to the structural components sensitive to the allosteric switch in the transition state.
When PC is used as substrate, the slow form cleaves with higher specificity. PC is the first substrate found to be more specific for the slow thrombin form (see Fig. 3 , where the effect is illustrated in the form of progress curves of S2266 hydrolysis). Release of p-nitroaniline is more pronounced when thrombin is in the fast form, but this is due to a higher specificity of thrombin and APC toward S2266 with Na+ (see Materials and Methods). The contribution of PC activation (Eq. 4) must be decoupled from the progress curves using the information derived independently on substrate hydrolysis by thrombin and APC (Eqs. 5 and 6). When this decoupling is done, specificity of thrombin for PC is greater in the slow form. This conclusion is illustrated directly by simulated progress curves. The formation of p-nitroaniline can be simulated by swapping the kcat/Km values obtained for PC activation in Eq. Table 2 . Table 2 . Discontinuous lines (---) simulate the progress curves that would be observed if the fast form cleaved PC with the same specificity as found experimentally for the slow form (see Table 2 ). Discontinuous-dotted (--) lines simulate the progress curves that would be observed if the slow form cleaved PC with the same specificity as found experimentally for the fast form (see Table 2 ). The simulated curves show directly that the slow form cleaves PC with higher specificity. 4 by the slow and fast forms (see Table 2 ), while keeping all other rates in Eqs. 5 and 6 unchanged. This result yields two curves: one (discontinuous line in Fig. 3 ) depicting the progress curve that would be measured if the fast form cleaved PC with the specificity found experimentally for the slow form, and the other (discontinuous-dotted line) depicting the progress curve that would be measured if the slow form cleaved PC with the specificity determined experimentally for the fast form. The actual progress curve with thrombin in the fast form lies below the simulated one, whereas that of the slow form lies above the simulated curve. Hence, the slow form cleaves PC with higher specificity.
Preferential cleavage of PC by the slow form is a crucial observation for understanding the structural basis of thrombin specificity. The results obtained in the presence of 10 nM TM likely underestimate the preferential cleavage by the slow form because TM binds with higher affinity to the fast form. Measurements done as a function of TM concentration confirm the preferential cleavage of PC by the slow form under saturating concentrations of TM, measurements that are difficult to achieve in practice. The kcat/Km values obtained for the fast form are consistent with the results of previous studies (19, 21) , where the specificity was measured by quenching Eqs. 4-6 at different time intervals and assaying APC activity. The experimental strategy based on the analysis of progress curves, introduced in the present study, provides results that are accurate and reliable and has the desirable practical advantage of requiring smaller amounts of material.
The specificity of thrombin for PC is drastically reduced in the presence of Ca2+ in both the slow and fast forms. This result is consistent with previous findings obtained in the presence of 0.1 M NaCl (22, 23) . The effect is due to a conformational change of PC induced by Ca2+ binding to a high-affinity site in the region homologous to the Ca2+ binding loop of chymotrypsin (23, 24) . However, Ca24 increases the specificity when TM is present. As a result, the effect of TM in switching thrombin specificity toward PC changes from a factor of -5-8 in the absence of Ca24 to a factor of 600-800 in the presence of Ca2+. These results agree with previous findings obtained in the presence of NaCl and in the absence of a phospholipid surface (19, 21) .
DISCUSSION
A crucial issue in the study of blood coagulation is to understand the rules for specificity and regulatory interactions that give rise to the efficiency of the hemostatic process. The coagulation cascade was originally conceived as a mechanism to amplify the response to acute vessel injury downstream to the generation of thrombin and formation of the fibrin clot (25, 26) . However, efficient coagulation requires that the response be localized to the site of injury, be rapidly achieved, and be terminated. This task is accomplished by carefully articulated mechanisms of regulation (1, 2) and especially by the anticoagulant feed-back mechanisms centered around the action of TM and PC (6) . The results reported here broaden our understanding of molecular recognition and regulation in blood coagulation. The observation that antagonistic roles in hemostasis can be targeted toward distinct allosteric forms of a protease is unprecedented. The slow and fast forms of thrombin have been targeted toward the anticoagulant and procoagulant activities of the enzyme, as illustrated in Fig. 4 . Fibrinogen is cleaved by the fast form with higher specificity, whereas PC is cleaved by the slow form with higher specificity. By linkage principles, it follows that fibrinogen binding promotes the slow--fast transition, whereas the opposite is seen upon binding of PC. The role of TM in the regulation of thrombin function is crucial and can be understood in terms of the effect on the slow+-fast equilibrium. In the absence of TM, the procoagulant role of thrombin prevails because the fast form is more populated and cleaves fibrinogen with higher efficiency. In the presence ofTM, the fast form is preferentially inhibited because TM binds to this form with higher affinity. This mechanism provides the most effective way of switching thrombin into an anticoagulant enzyme. Once the fast form is inhibited and can no longer cleave fibrinogen, the anticoagulant role of the slow form prevails, leading to efficient activation of PC.
The major driving force for the slow-*fast transition is provided by the binding of Na+ to a single site (9, 10) . The equilibrium between the slow and fast forms of the free enzyme is set by the amount of Na+ in the blood (9, 11 
